MAPK8IP2 and neoplasm: The expression of MAPK8IP2 was significantly correlated with Gleason score (P <  0.001), T stage (P <  0.001), N stage (P = 0.002), primary therapy outcome (P = 0.048), and residual tumor (P = 0.009), but not with age, prostate specific antigen (PSA), M stage, race, and zone of origin, as shown in Table 1.